G1 Therapeutics, Inc. announced that it has named Seth Rudnick, M.D. as executive chairman of its board of directors, effective immediately. Dr. Rudnick has been serving as the chair of G1's Scientific Advisory Board for the past year and will continue in this role with the company. Dr. Rudnick brings to G1 extensive expertise in oncology, drug discovery and development and healthcare investments.

He is recently retired from Canaan Partners. Dr. Rudnick was a Yale Fellow in medical oncology where he was also a Robert Wood Johnson Scholar.